Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. (symbol: MEDP) is a leader in research-based drug development, renowned for its therapeutically focused approach. As a full-service global clinical research organization (CRO), Medpace partners strategically with select sponsors to streamline the path to drug approval, ensuring efficiency and cost-effectiveness. Headquartered in Cincinnati, the company extends its operations across six continents, encompassing Europe, Asia, South America, Africa, and Australia. With a workforce exceeding 5,400 employees spread across 40 countries, Medpace delivers customized solutions to both small and midsize biotechnology firms, as well as full-service offerings for global pharmaceutical companies.
Founded over 30 years ago, Medpace leverages its extensive medical and regulatory expertise to offer strategic insights and efficiencies at every phase of clinical trials. The company’s comprehensive services include bioanalytical laboratory services and advanced imaging capabilities, aimed at supporting the complex demands of drug development. Medpace’s commitment to high-quality service positions it as a steward of its clients’ drugs, from early-stage development through to final approval.
In 2014, Medpace was acquired by Cinven, a global private equity firm, for $915 million, with Cinven ending its investment in 2018. Despite this change in ownership, Medpace's dedication to advancing medical research and drug development remains steadfast. The company continues to forge strong partnerships and deliver superior results tailored to the unique needs of its clients.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported robust financial results for Q1 2023, with revenue of $434.1 million, up 31.2% year-over-year. The company achieved a net book-to-bill ratio of 1.28x, with net new business awards of $555.8 million, a 31.4% increase. GAAP net income rose to $72.9 million or $2.27 per diluted share, compared to $61.3 million or $1.69 per diluted share last year. EBITDA increased 31.9% to $92.8 million, yielding an EBITDA margin of 21.4%. The company projects 2023 revenue between $1.745 billion and $1.805 billion, reflecting growth of 19.5% to 23.6%.
Cash flow from operations reached $80.1 million, with a remaining $332.7 million for share repurchase. Medpace will host a conference call on April 25, 2023, to further discuss these results.
Medpace Holdings (Nasdaq: MEDP) will report its Q1 2023 financial results on April 24, 2023, after market close. A conference call is scheduled for April 25, 2023, at 9:00 a.m. ET to discuss these results. Interested participants can register in advance through a provided link and are encouraged to join 10 minutes early. The call will also be accessible via webcast on Medpace's investor relations website, where a replay will be available afterwards. Additionally, a supplemental slide presentation will be posted on the site prior to the call.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a 27.7% increase in fourth-quarter 2022 revenue, reaching $394.1 million, compared to $308.6 million in Q4 2021. The net income for Q4 2022 rose to $68.7 million or $2.12 per diluted share, up from $50.0 million or $1.32 per diluted share the previous year. Full-year 2022 revenue was $1,460.0 million, a 27.8% increase. The company forecasts 2023 revenue between $1.690 billion and $1.750 billion, implying growth of 15.8% to 19.9%.
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its fourth quarter and fiscal year 2022 financial results on February 13, 2023, after market close. A conference call is scheduled for February 14, 2023, at 9:00 a.m. ET to discuss these results. Participants can register in advance through the provided link. The call will also be accessible via webcast on Medpace's investor website, with a replay available after the event. Medpace is a global clinical contract research organization offering comprehensive services across various therapeutic areas.
Medpace Holdings, Inc. (NASDAQ: MEDP) reported third-quarter 2022 revenue of $383.7 million, up 29.8% year-over-year. Net new business awards reached $470.9 million, yielding a net book-to-bill ratio of 1.23x. GAAP net income was $66.0 million or $2.05 per diluted share, compared to $48.6 million or $1.29 in Q3 2021, with a net income margin of 17.2%. EBITDA increased 48.5% to $89.3 million. The outlook for 2022 anticipates revenue of $1.440 billion to $1.460 billion.
Medpace Holdings, Inc. (Nasdaq: MEDP) will release its third quarter 2022 financial results after market close on October 24, 2022. A conference call will follow on October 25, 2022, at 9:00 a.m. ET to discuss these results. Interested parties can register here. A supplemental slide presentation will be available in the 'Investors' section of their website.
Medpace Holdings, Inc. (MEDP) reported a revenue of $351.2 million for Q2 2022, a 26.2% increase from $278.3 million a year earlier. Net new business awards rose by 16.3% to $450.6 million, achieving a net book-to-bill ratio of 1.28x. The company posted a GAAP net income of $49.4 million, or $1.46 per diluted share, marking a significant increase from the $39.9 million in Q2 2021. EBITDA climbed 42.0% to $68.1 million, equating to a margin of 19.4%. Medpace forecasts 2022 revenue between $1.405 billion and $1.435 billion.
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its Q2 2022 financial results on July 25, 2022, after market close. A conference call is scheduled for July 26, 2022, at 9:00 a.m. ET to discuss the results. Interested participants can register via a provided link or join through the investors section of the Medpace website. A supplemental slide presentation will also be made available ahead of the call. Medpace is a full-service clinical contract research organization focusing on biotechnology, pharmaceuticals, and medical devices.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
What services does Medpace Holdings, Inc. provide?
Where is Medpace Holdings, Inc. headquartered?
How many employees does Medpace have?
In how many countries does Medpace operate?
When was Medpace founded?
Who acquired Medpace in 2014?
Does Medpace focus on any specific industries?
What expertise does Medpace bring to its partnerships?
Did Cinven exit its investment in Medpace?
What is Medpace's approach to drug development?
